2023 World Conference on Lung Cancer (Posters)-EP07.05. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

EP07.05. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial - PDF(Abstract)

Back to course

Pdf Summary

Aumolertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown promising results as neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC) with EGFR mutations. This study presents a subcohort analysis of the PURPOSE trial, which is an umbrella study of neoadjuvant therapy for resectable NSCLC.<br /><br />The study included six patients with EGFR 19del mutations who received Aumolertinib orally for 9 weeks followed by surgery. The primary endpoint was the objective response rate (ORR), and secondary endpoints included major pathologic response (MPR) rate, pathological complete response (pCR) rate, event-free survival (EFS), overall survival (OS), and perioperative outcomes.<br /><br />Of the six patients who completed neoadjuvant treatment, four were females and two were males, with a median age of 63 years. Five patients had lung adenocarcinoma, and one had squamous cell carcinoma. Notably, the ORR was 100%, with two patients achieving pCR and one achieving MPR. All patients achieved R0 resection, and the rate of mediastinal lymph node downstage was 83.3%. Only one patient experienced a Grade 1 adverse event of oral ulceration.<br /><br />The results of this subcohort analysis suggest that Aumolertinib as neoadjuvant therapy is effective and feasible for locally-advanced EGFR 19del NSCLCs. The full results of the PURPOSE trial will be released in the future.<br /><br />Overall, this study provides evidence that Aumolertinib can be a promising option for neoadjuvant therapy in EGFR-mutated NSCLC patients, potentially pushing the boundaries in the treatment of early-stage disease.

Asset Subtitle

Yi-Yang Wang

Meta Tag

Speaker Yi-Yang Wang

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

Aumolertinib

EGFR

tyrosine kinase inhibitor

neoadjuvant therapy

resectable non-small cell lung cancer

EGFR mutations

PURPOSE trial

objective response rate

major pathologic response

pathological complete response